REG-Arix Bioscience PLC Arix Managing Director to Participate in Fireside Chat at the Jefferies Healthcare Conference

Arix BioscienceAnnouncement

08/11/2021 07:05

============

   Arix Bioscience PLC (ARIX)
   Arix Managing Director to Participate in Fireside Chat at the Jefferies
   Healthcare Conference

   08-Nov-2021 / 07:00 GMT/BST
   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

                                        

    

                                        

                              Arix Bioscience plc

    Arix Managing Director to Participate in Fireside Chat at the Jefferies
                             Healthcare Conference

                                        

   LONDON, 8 November  2021: Arix Bioscience  plc ("Arix"  or the  "Company")
   (LSE: ARIX), a global venture capital company focused on investing in  and
   building breakthrough biotech companies,  today announces that Mark  Chin,
   Managing Director, is  scheduled to participate  in a virtual  analyst-led
   fireside chat with  Matthew Hose,  Equity Research  Analyst, at  Jefferies
   London Healthcare Conference  taking place  in person  and virtually  from
   16-19 November 2021 in London.

    

   A webcast  of  the  fireside  chat will  be  available  on  the  Jefferies
   conference portal  and the  replay  will be  available afterwards  on  the
   Investor Relations section of Arix's website  1 here.

                                        

                                      ENDS

    

   Enquiries

    

   For more information on Arix, please contact:

   Arix Bioscience plc
   +44 (0) 20 7290 1050
    2 ir@arixbioscience.com

    

   Optimum Strategic Communications

   Mary Clark, Manel Mateus
   +44 (0)20 8078 4357
    3 optimum.arix@optimumcomms.com

    

   About Arix Bioscience plc

   Arix Bioscience  plc  is  a  global venture  capital  company  focused  on
   investing  in   and  building   breakthrough  biotech   companies   around
   cutting-edge advances in life sciences.

    

   We collaborate  with exceptional  entrepreneurs and  provide the  capital,
   expertise  and  global  networks  to  help  accelerate  their  ideas  into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting  growth phase of  our industry to  a broader range  of
   investors.  4 www.arixbioscience.com

    

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  MSCM
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   126161
   EQS News ID:    1246669


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    5 fncls.ssp?fn=show_t_gif&application_id=1246669&application_name=news&site_id=refinitiv

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=86da155cafdf30ac7526f4c2a3d85d4e&application_id=1246669&site_id=refinitiv&application_name=news
   2. mailto:ir@arixbioscience.com
   3. mailto:optimum.arix@optimumcomms.com
   4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1246669&site_id=refinitiv&application_name=news


============